Form 4: Labcorp Executive Mark S. Schroeder Executes Stock Options and Sells Shares
SEC Form 4 Filing
Labcorp's EVP, Pres Diagnostics & COO, Mark S. Schroeder, exercised stock options and sold a portion of the acquired shares on February 28, 2025, according to a recent SEC filing.
Summary
- Mark S. Schroeder, EVP, Pres Diagnostics & COO of Labcorp Holdings Inc., executed non-qualified stock options on February 28, 2025, acquiring 3,903 shares of common stock at a price of $131.43.
- On the same day, Schroeder sold 5,339 shares of common stock at $249.23 per share.
- These transactions were conducted pursuant to a pre-arranged plan under Rule 10b5-1.
- Following these transactions, Schroeder directly owns 4,960.1426 shares of Labcorp common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting insider trading activity. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives, which is important for investors to monitor.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 02/12/2020 | Date from which the employee stock options vested in three equal annual installments. |
| 02/28/2025 | Date of the stock option exercise and stock sale. |
| 03/04/2025 | Date of the signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.